Indefinite Delivery Contract SPE2DB25D9768

This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued up to $499,999,999, covers the period from October 2, 2024 through December 31, 2025.

Under this IDC, DMS Pharmaceutical Group will provide a comprehensive range of pharmaceutical products and medical supplies to fulfill the recurring medical needs of military health facilities worldwide. This includes branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables such as flumazenil injections, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, contraceptives, oncology drugs, and specialty medications. The contract allows the DLA to issue firm fixed-price delivery orders for these items, which will be primarily distributed through the DLA's Medical Supply Chain division to various Department of Defense (DoD) healthcare facilities globally. This IDC complements DMS Pharmaceutical Group's existing prime vendor contracts for direct pharmaceutical distribution and pharmacy services to DoD sites, solidifying the company's role as a crucial supplier in the federal pharmaceutical supply chain.